用免疫疗法治疗的晚期皮肤状细胞癌中围神经扩散的评估
Karda Cavanagh1, Luke S McLean2,3, Annette M Lim2,3
1Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
概括
免疫疗法显示皮肤状细胞癌与周围神经扩散 (PNS) 的高响应率,根据修改的MRI标准进行评估. 这些反应与RECIST 1.1一致,表明免疫疗法.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 皮肤状细胞癌 (CSCC) 经常涉及周围神经系统 (PNS) 的扩散,与糟糕的结果相关.
- 免疫疗法是高级CSCC的新标准,提供持久的反应.
- 像RECIST 1.1这样的当前标准无法捕捉PNS,需要新的评估方法.
研究的目的:
- 评估晚期CSCC患者的PNS对免疫治疗的放射性反应.
- 评估修改后的分级系统对MRI上PNS反应的有用性.
- 探索PNS反应,RECIST 1.1和FDG-PET/CT发现之间的相关性.
主要方法:
- 对20名先进的CSCC患者进行了回顾性审查,这些患者患有PNS并接受免疫治疗 (2018年4月-2022年2月).
- 主要结局:使用MRI<5,5-10,>10个月的分级标准对盲目放射性PNS反应的评估.
- 二次结果:与RECIST 1.1的相关性以及对FDG-PET/CT.的PNS的评估.
主要成果:
- 70%的患者在5个月后表现出PNS反应.
- 在MRI上PNS反应在很大程度上与>10个月的RECIST 1.1一致 (科恩的卡帕0.62).
- 在5/14例中,FDG-PET/CT显示可疑的PNS特征,表明敏感性有限.
结论:
- 修改后的MRI标准可以有效地记录CSCC中免疫疗法诱导的PNS反应.
- 观察到PNS对免疫疗法的高反应率,与RECIST 1.1相关.
- 在这种情况下,FDG-PET/CT对检测PNS的灵敏度有限.
相关概念视频
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


